

## 83.1. Leukemia: Acute Myeloid Leukemia

---

### Authors

Jerald P. Radich, Soheil Meshinchi, Elihu H. Estey, William L. Carroll, Ryan Cassaday, Steven Coutre, Elaine S. Jaffe, John P. Leonard

### Emerging Prognostic Factors for Clinical Care

<b>Factor</b>	<b>Definition</b>	<b>Clinical Significance</b>	<b>Level of Evidence</b>
Clearance of mutations after induction therapy	Assessed by exome or whole genome sequencing	Patients with persistence of mutations had shorter remissions than patients without persistence	III <sup>1</sup>

### Risk Assessment Models

The AJCC recently established guidelines that will be used to evaluate published statistical prediction models for the purpose of granting endorsement for clinical use.<sup>2</sup> Although this is a monumental step toward the goal of precision medicine, this work was published only very recently. Therefore, the existing models that have been published or may be in clinical use have not yet been evaluated for this cancer site by the Precision Medicine Core of the AJCC. In the future, the statistical prediction models for this cancer site will be evaluated, and those that meet all AJCC criteria will be endorsed.

### Recommendations for Clinical Trial Stratification

The authors have not provided any recommendations for clinical trial stratification at this time.

### Bibliography

1. Moricke A, Zimmermann M, Reiter A, et al. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. *Klin Padiatr.* 2005;217(6):310-320.
2. Kattan MW, Hess KR, Amin MB, et al. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. *CA: a cancer journal for clinicians.* 2016.